Ježková Kateřina

abstract pro akci: 17. KONGRES O ATEROSKLERÓZE, 05.12.2013 - 07.12.2013 - Hotel
Harmony Club, Špindlerův Mlýn
téma: EXPERIMENTAL MOUSE MODEL WITH HIGH LEVELS OF
HUMAN SOLUBLE ENDOGLIN – A PILOT STUDY
forma prezentace: poster
vložil: Kateřina Ježková Mgr.
EXPERIMENTAL MOUSE MODEL
WITH HIGH LEVELS OF HUMAN
SOLUBLE ENDOGLIN – A PILOT
STUDY
autoři: K.Ježková, J. Rathouská, I. Němečková, P. Nachtigal Department of Biological and
Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague,
Czech Republic
Soluble form of endoglin (s-endoglin) is generated by a cleavage from tissue endoglin
(CD105). Soluble endoglin was proposed to be a marker or a possible cause of endothelial
dysfunction in diabetes, hypertension and atherosclerosis in humans and mice. This pilot
study was aimed to describe basic characteristics of mice overexpressing human soluble
endoglin.
Transgenic mice expressing human soluble endoglin on CBAxC57BL/6J background
(Sol.eng+), were generated at the University of Salamanca (Spain). Four months old male
(n=9) and female (n=17) mice on chow diet were used. Plasma was extracted from a tail tip
and the levels of human soluble endoglin were determined by ELISA.
ELISA analysis showed that only four Sol.eng+ males and seven Sol.eng+ females were
positive for high levels of soluble endoglin (s-endoglin > 1000 ng/ml). Other Sol.eng+ mice
reached only low levels of soluble endoglin.
In conclusion, this pilot study shows that only 1/3 of transgenic mice express high levels of
soluble endoglin. Other mice can be used as control mice with low levels of soluble endoglin.
Sol.eng+ will be used as an experimental model that should elucidate a possible development
of endothelial dysfunction in relation to high levels of soluble endoglin.
The study was supported by grant from The Grant Agency of Charles University in Prague
number 300911/C and grant SVV/2013/267003.